BNP Paribas Financial Markets’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-2,571
Closed -$47.3K 4232
2020
Q4
$47.3K Sell
2,571
-478
-16% -$8.71K ﹤0.01% 3579
2020
Q3
$55.9K Buy
3,049
+2,583
+554% +$43.4K ﹤0.01% 3422
2020
Q2
$6.98K Sell
466
-3,292
-88% -$47K ﹤0.01% 3867
2020
Q1
$59.5K Buy
3,758
+1,670
+80% +$27K ﹤0.01% 3460
2019
Q4
$33.9K Buy
2,088
+162
+8% +$2.7K ﹤0.01% 3845
2019
Q3
$28.6K Buy
1,926
+333
+21% +$4.49K ﹤0.01% 3777
2019
Q2
$26.3K Sell
1,593
-863
-35% -$14.1K ﹤0.01% 3797
2019
Q1
$42.5K Buy
2,456
+2,315
+1,642% +$42K ﹤0.01% 3597
2018
Q4
$2.49K Sell
141
-238
-63% -$4.04K ﹤0.01% 3759
2018
Q3
$6.88K Sell
379
-8
-2% -$164 ﹤0.01% 3914
2018
Q2
$7.57K Buy
387
+380
+5,429% +$7.12K ﹤0.01% 3911
2018
Q1
$123 Hold
7
﹤0.01% 4147
2017
Q4
$79 Hold
7
﹤0.01% 4147
2017
Q3
$75 Hold
7
﹤0.01% 4162
2017
Q2
$61 Sell
7
-58
-89% -$511 ﹤0.01% 4189
2017
Q1
$767 Sell
65
-167
-72% -$2.03K ﹤0.01% 3755
2016
Q4
$3.04K Sell
232
-672
-74% -$8.99K ﹤0.01% 3846
2016
Q3
$13.1K Buy
904
+231
+34% +$3.28K ﹤0.01% 3096
2016
Q2
$8.07K Buy
673
+593
+741% +$9.53K ﹤0.01% 3022
2016
Q1
$1.49K Sell
80
-1,676
-95% -$27.8K ﹤0.01% 2461
2015
Q4
$37.7K Sell
1,756
-735
-30% -$15.5K ﹤0.01% 2999
2015
Q3
$42.2K Buy
2,491
+1,672
+204% +$41.6K ﹤0.01% 2989
2015
Q2
$30.7K Buy
+819
New +$26.4K ﹤0.01% 2780

BNP Paribas Financial Markets's CBMG Position: Q1 2021 in Review

BNP Paribas Financial Markets sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 2,571 shares — an estimated $47.3K sold.

BNP Paribas Financial Markets first reported a position in CBMG in Q2 2015 and held it in 23 quarters. The position peaked at $59.5K in Q1 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • BNP Paribas Financial Markets reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 2,571 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $47.3K.
  • BNP Paribas Financial Markets first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 23 quarters.
  • BNP Paribas Financial Markets's Cellular Biomedicine Group, Inc. position peaked at $59.5K in Q1 2020.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2021, filed 7 May 2021.